UK Markets close in 5 hrs 14 mins

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
252.09+3.73 (+1.50%)
At close: 04:00PM EDT
252.84 +0.75 (+0.30%)
Pre-market: 05:45AM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • S
    Affirms full year guidance
  • S
    They slightly lowered top line revenue guidance to account for the acquisition of CCXI. Always a second shoe drops with AMGN earnings report.
  • E
    Half their cash for a 1 trick pony and $65B in debt.
  • K
    The pick that was just sent out by ( is already up yuge! Check it out!
  • o
    AMGN looks like it is about to drop. Be careful guys. I have been reading ( and their stocks have been doing way better.
  • p
    Amgen Battles With the IRS Over Its $10.7 Billion Tax Bill
    reported today inWall Street Journal
  • S
    I hope they don't disappoint us AGAIN!
  • k
    There is a new virus (LayV)found in china and it is treated with antiviral. There is a future for TPOXX....More opportunity in future....
  • k
    AMGN needs to buy CRDF, Hello AMGN get it before Pfizer does.
  • S
    Perfect time to invest in AMGN. Write call options if you are nervous. Watch IBB and XBI.
    AND don't forget another increase in dividend to be announced on or about December 15. I expect minimum of 10% increase to $8.50+ per year.
  • A
    Bertrand delsuc:

    $AMGN gives up in BCMA race

    Pavurutamab (AMG 701)

    Clinical development of pavurutamab an anti-B-cell maturation antigen (BCMA) HLE BiTE molecule being investigated for the treatment of multiple myeloma, has been discontinued for strategic reasons.


    Going to be nearly impossible for bi-specifics to compete with CAR-T efficacy in BCMA. Hard to see where they fit in.


    also hard to see how other CAR-BCMA programs compete once JNJ gets the wheels turning on cilta-cel

    Thoughts peter?
  • S
    Big miss at LLY may lean on pharmaceuticals
  • S
    Beat on top and bottom line
  • S
    If management blames competitors again I think I'll scream 😱
  • R
    I know a guy that was buying AMGN on a weekly when it was trading at $1.00 lol
  • N
    $AMZN conversation
    $AMGN In the recent reporting quarter: 17.23% of institutions made no changes to their position.
  • m
    michael k
    Long time Amgen holder since 2001. I hate to say it but every time they get close to a double top they always break down and never break out. They have a history of this. They should be a $300 plus stock by
    Now but it just doesn't happen... sadly there always seem to be an excuse as to why. Since I bought in at $68 in 2001 and based on that price and what the dividend is now that's about a 12% return on original investment. However, they still should be trading at a 6 to 8x from where I bought it. Oh well maybe one day they will break to the upside "when someone bigger acquires them"...
  • k
    The five-year chart looks great - lower left to upper right at about a 35-degree angle.
  • j
    $ARWR conversation
    Credit Truth on twitter:
    Notable that $AMGN is demonstrating a new level of confidence in $ARWR TRiM
    Trade mark sign
    by their manner of promoting progress with Lipoprotein(a) w/ AMG-890 formerly Arrowhead’s ARO-LPA
    Seems this blockbuster drug is moving quickly enough to merit this Amgen PR.
    10 Things to Know About Lipoprotein(a) - Amgen Science